Cervical Cancer Diagnostic Test Market to Exhibit Profitable Growth During the Forecast Period
The global cervical cancer diagnostic test market was growing significantly and was valued at US$ 8,779.2 million in 2017; it is expected to attain US$ XX million by 2026. The growing prevalence of cervical cancer worldwide, as well as a growing female population aged 25 to 60 years, are the major factors driving the global cervical cancer diagnostic test market. In addition, new technological progress in HPV testing and Pap (Papanicolaou) testing is generating major revenue in the developed markets. Also, favorable private and public initiatives in the medical sector across various developing countries, product expansion, and increasing lab tests with higher acceptance of instruments and kits will further assist in the overall cervical cancer diagnostic test market growth.
The Pap test segment was leading the worldwide market in 2017. The Pap (Papanicolaou) test is a screening test that is generally used to determine cervical health. Enhanced Pap test screenings have made it simpler for doctors and specialists to discover cancerous cells. Digital screening, regularly called Focal Point or AutoPap, utilizes a computer to filter the sample for abnormal cells. The improvement in computer-guided cancer tests to minimize errors and improve precision is expected to drive the growth of the market. Pap tests give continuous comprehension of current cell development and demonstrate whether strange cell development is probably going to wind up malignant in the near term if left untreated. Furthermore, the HPV (Human Papillomavirus) test is utilized to recognize diseases with high-hazard HPV, the infection that causes cervical disease. Over 90% of cervical malignancies happen because of HPV infection, and they are analyzed through Pap smear screening and HPV testing. The two most well-known types of cervical cell tumors are adenocarcinoma and squamous cell carcinoma.
Various screening tests for females with symptoms of cervical cancer or abnormal Pap results include past medical history and physical examination, colposcopy, cervical biopsies, endocervical curettage (endocervical scraping), cone biopsy, loop electrosurgical procedure (LEEP, LLETZ), cold knife cone biopsy, and other imaging tests such as chest x-ray, computed tomography (CT), magnetic resonance imaging (MRI), intravenous urography, and positron emission tomography (PET) scan.
Various external factors contribute to the expanding prevalence of cervical disease around the world. These include a rising number of female smokers, a huge number of patients experiencing HPV contamination, a developing obese population (age group 21–60 years), and expanding occurrences of unsafe sex, especially among youngsters. Cancer awareness programs and early diagnosis likewise contribute to the development of this market. Cervical cancer diagnostic tests, as well as advanced laboratory testing procedures, are driving up demand, particularly in the Asia Pacific and Europe.
Inaccurate Pap smear testing, low-grade vaccination, ineffectual medical service foundations and cancer institutes, less awareness about cervical malignancy, stringent government regulations, and a cheap and alternative approach toward cervical cancer diagnosis in developing nations are a few external factors that hinder the development of the worldwide cervical cancer diagnostic test market. New and advanced technology assessment in laboratory testing, an increasing population in developing nations such as India, China, Brazil, and others, and healthcare infrastructure improvements in rising economies are factors spurring revenue growth in this market.
Other prominent drivers include low immunity factors in women working in developing countries due to a deficiency in the right nutritional intake, an upsurge of human papillomavirus in females, higher usage of oral contraceptive pills by females, and having multiple sex partners with unsafe sex.
Market Synopsis
The Pap Test Type Segment is expected to register higher growth in the Developing Nations by the end of 2026.
In the past decade, various studies and research have shown that the regular history of corrective diagnostic testing has significantly affected the rate of cancer worldwide.
A Pap test, also known as a Pap smear, is the most widely recognized test for detecting early changes in cells that can lead to cervical cancer. It includes gathering a sample of cells from the cervix. A portion of the cells collected from the cervix during a Pap smear test may also be tested for human papillomavirus or HPV. Contamination with HPV is a risk factor for cervical tumors. Pap smear tests give an ongoing comprehension of current cell development and show whether abnormal cell development is probably going to become more cancerous in the near term if left untreated.
According to the American Cancer Society and the World Health Organization, top-quality screening with Pap and HPV tests has extraordinarily lessened mortality from cervical cancer. Since the introduction of Pap testing in the U.S. in the 1950s, cervical tumors, once the most common reason for deaths due to malignancy in females, now rank fourteenth, which denotes a 70 percent decrease over that time range. This decrease in mortality is the immediate consequence of Pap and HPV diagnostics that have expanded the detection of cervical cancer at the beginning of the diagnosis, lessening the general frequency of cervical cancer worldwide.
In April 2014, the U.S. FDA approved the utilization of a single HPV DNA test (the COBAS test, by Roche) as a first-line principal screening test for use only in females aged 25 years and older. This particular test identifies each of the HPV types, mainly 18 and 16, and gives collective marks for 12 supplementary risky HPV categories.
In Developing Economies, the rising prevalence of cervical cancer, combined with advanced diagnostic procedures, is gaining traction.
North America spearheaded the market in 2017 owing to the presence of established players and increasing incidences of cervical cancer in the U.S., as indicated by a report published by the American Cancer Society, in which around 4000 females died due to cervical cancer. As per the research study, the American Cancer Society's projections for cervical cancer in the U.S. for 2018 are that around 13,000 fresh cases of cervical cancer will be diagnosed in females, and around 4,100 females will die from this disease. However, deaths from cervical cancer in the U.S. keep declining by around 2 percent a year. This decrease is largely due to the increased use of the Pap test to identify cervical variations and permit early treatment.
Expanding the number of techniques for cervical cancer diagnostic tests alongside rising approvals from the U.S. FDA is relied upon to drive the development of the worldwide cervical cancer diagnostic test market. The rising trend of HPV test procedures alone in the U.S. and Europe, along with increasing awareness for new computerized diagnostic tests and cervical cancer screening programs, is gaining momentum in the global market.
Moreover, Asia Pacific is relied upon to indicate fast development in the cervical cancer diagnostic test market, attributable to expanding R&D and approval of novel test kits and instruments in India and China. Furthermore, rising cervical cancer prevalence increased acceptance of international brands in developing countries, technology assessment with increased FDA approval for Pap and HPV testing, and a growing need for advanced diagnostic procedures such as colposcopy, cystoscopy, cone biopsy, and imaging tests, as well as increased awareness, are expected to drive the cervical cancer diagnostic tests market during the forecast period.
Market penetration for emerging players is difficult due to the dominance of established multinational players with strong product portfolios.
Major players in the cervical cancer diagnostic test market are Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., Siemens Healthcare, Guided Therapeutics Inc., Ascon Medical Instruments Pvt. Ltd., Hoffmann-La Roche, Cooper Surgical Inc., Cardinal Health, Inc., Beckman Coulter Inc., and others. These manufacturers are implementing growth strategies along with new technology assessments, approvals for new diagnostic kits and instruments for cancer, and partnerships with medical technology companies to increase economic benefits. Roche developed the CINtec PLUS automated cytology test in 2014 to remove unhealthy tissue from the cervix site prior to the growth of cancerous cells. Furthermore, Roche announced that Avastin, a combination of medicine and chemotherapy for treating patients with advanced cervical cancer, had received FDA approval in the United States.
Periods of History and Forecast
This study report includes an analysis for each segment from 2016 to 2026, with 2017 as the base year. The compound annual growth rate (CAGR) for each of the respective segments is estimated for the forecast period from 2018 to 2026.
Report Scope by Segments
The cervical cancer diagnostic test market comprises current market trends and dynamics along with a quantitative analysis of the global market. The report elucidates thorough information about the global cervical cancer diagnostic test market by segmenting the market in terms of product, modality, end-user, and geography. This report will assist healthcare professionals and market participants in making decisions and strategizing market positions.
The current report also encompasses qualitative market assessment factors such as market trends, key market drivers, restraints, and opportunities that give a better understanding of the overall cervical cancer diagnostic test market. Furthermore, the report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolios, and business strengths. Key industrial players profiled in the study report are Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., Siemens Healthcare, Guided Therapeutics Inc., Ascon Medical Instruments Pvt. Ltd., Hoffmann-La Roche, Cooper Surgical Inc., Cardinal Health, Inc., Beckman Coulter Inc., and others.
Key questions are answered in this report.
What are the current market trends and dynamics in the cervical cancer diagnostic test market, and what are the valuable opportunities for emerging players?
What is the market positioning of the major market players?
Which segment accounts for the fastest CAGR during the forecast period?
Which end-user holds a larger market share and why?
What is the impact of the high cost of screening tests on the cervical cancer diagnostic test market?
Are low- and middle-income economies investing in the cervical cancer diagnostic test market?
What are the market trends and dynamics in emerging markets such as Japan, Latin America, the Middle East, and Africa?
Frequently Asked Questions:
The market for Cervical Cancer Diagnostic Test Market is expected to reach US$ XX Bn by 2026.
The Cervical Cancer Diagnostic Test Market is expected to see significant CAGR growth over the coming years, at XX%.
The report is forecasted from 2018-2026.
The base year of this report is 2017.
Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., Siemens Healthcare, Guided Therapeutics Inc., Ascon Medical Instruments Pvt. Ltd., Hoffmann-La Roche, Cooper Surgical Inc., Cardinal Health, Inc., Beckman Coulter Inc. are some of the major players in the global market.
